OCUGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Ocugen, Inc. on Behalf of Ocugen Stockholders and Encourages Investors to Contact the Firm
April 02, 2024 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Ocugen, Inc. (“Ocugen” or...
SHAREHOLDER ALERT: Ocugen Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
April 02, 2024 11:06 ET
|
Block & Leviton LLP
BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Ocugen, Inc. (NASDAQ: OCGN) for potential securities law violations. Investors who have lost money in their Ocugen,...
Ocugen to Present at Pharma Market Research Conference
January 31, 2024 08:00 ET
|
Ocugen
MALVERN, Pa., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen Provides Business Update with Third Quarter 2023 Financial Results
November 09, 2023 06:30 ET
|
Ocugen
Conference Call and Webcast Today at 8:30 a.m. ET OCU400 demonstrated favorable safety and tolerability profile in retinitis pigmentosa (RP) and Leber congenial amaurosis (LCA) subjects Completed...
Ocugen, Inc. Announces Connie Collingsworth Joins Business Advisory Board
September 21, 2023 07:30 ET
|
Ocugen
MALVERN, Pa., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen Provides Business Update with Second Quarter 2023 Financial Results
August 21, 2023 16:32 ET
|
Ocugen
Conference Call and Webcast Tomorrow at 8:30 a.m. ET • Investigational New Drug (IND) Applications Cleared for Novel Gene Therapies for Geographic Atrophy Secondary to AMD and for Stargardt Disease ...
Ocugen, Inc. Announces Adjournment of Annual Meeting of Shareholders
June 09, 2023 16:05 ET
|
Ocugen
MALVERN, Pa., June 09, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen to Host Conference Call on Friday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2023 Financial Results
April 28, 2023 07:00 ET
|
Ocugen
MALVERN, Pa., April 28, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen to Host Virtual Investor & Analyst Event on April 14, 2023
April 11, 2023 18:20 ET
|
Ocugen
MALVERN, Pa., April 11, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen Announces FDA Approval for Enrollment of Pediatric Patients in Ongoing OCU400 Phase 1/2 Clinical Trial for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)
March 27, 2023 08:00 ET
|
Ocugen
U.S. Food & Drug Administration (FDA) approves enrolling pediatric patients in the ongoing OCU400 Phase 1/2 trial who have: 1) RP associated with NR2E3 and RHO mutations and 2) LCA associated with...